Aruna D. Pradhan, MD, MPH, MSc
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Dr. Pradhan joined the faculty in 2005. She has joint appointments in the Division of Preventive Medicine at the Brigham and Women’s Hospital and Cardiovascular Medicine Division at the Veteran’s Administration Hospital, West Roxbury Campus. Her research interests span the related areas of inflammation, diabetes, and peripheral artery disease. Her early work demonstrated a strong link between subclinical inflammation and the development of diabetes. She continued this line of research as the Principal Investigator of the LANCET clinical trial which studied insulin therapy as a strategy to reduce inflammation among patients with diabetes during the initial stage of this disease. Other research activities pertain to the role of adipokines and other biologic markers having combined metabolic and inflammatory functions in the pathogenesis of diabetes and its vascular complications. As a recipient of a career development award from the National Heart, Lung, and Blood Institute to study risk factors for peripheral artery disease, Dr. Pradhan is also keenly interested in evaluating risk factors and underlying mechanisms that distinguish individuals at high risk for future coronary artery disease as compared to lower extremity artery disease. Dr. Pradhan is also a recipient of NIH funding to evaluate mechanisms of statin-associated diabetes in the JUPITER trial.
Dr. Pradhan completed her cardiovascular medicine fellowship at the Brigham and Women’s Hospital and continues her clinical activities as an echocardiographer and clinical cardiologist at the VA Boston Healthcare System, West Roxbury Campus.
MPH: Johns Hopkins University School of Hygiene and Public Health
MD: Georgetown University School of Medicine
MSc: Harvard School of Public Health
- Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009;302(11):1186-94.
- Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women’s Health Study. Circulation. 2011;123(24):2811-8.
- Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clin Chem. 2014;60(1):44-52.
- Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation. 2018;138(2):141-9.
- Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80-93.